ARPC1B Gene: As a Potential Novel Prostate Cancer Driver

Zaaluk, Hend

ARPC1B Gene: As a Potential Novel Prostate Cancer Driver

dc.contributor.advisor	Bismar, Tarek A.
dc.contributor.advisor	Riabowol, Karl T.
dc.contributor.author	Zaaluk, Hend
dc.contributor.committeemember	Argiropoulos, Bob
dc.contributor.committeemember	Lees-Miller, Susan
dc.contributor.committeemember	Eszlinger, Markus
dc.date	2020-06
dc.date.accessioned	2019-12-23T05:59:10Z
dc.date.available	2019-12-23T05:59:10Z
dc.date.issued	2019-12
dc.description.abstract	Prostate cancer is the most common malignancy in men and the second leading cause of cancer-related deaths in western countries. Currently, there is a lack of specific molecular markers that can predict cancer progression and prognosis. Characterization of prostate cancer driver genes is essential for investigating the cellular changes that influence the progression of cancer. This will provide a better understanding to prostate cancer carcinogenesis, elucidate novel biomarkers, and improve clinical outcomes. Previously our lab performed a bioinformatics screen using several public cohorts and identified a panel of genes that are deregulated on the mRNA and DNA levels. We hypothesize that these gene are potentially acting as oncogenes and tumor suppressors that could be related to the prognosis of prostate cancer. Actin-related protein -2/3 subunit B (ARPC1B) was found to be one of the most highly dysregulated genes. Dysregulation of ARPC1B expression has been detected in multiple human cancers and ARPC1B protein has been implicated in the control of actin polymerization. Moreover, ARPC1B is involved in many pathways such as cytoskeleton remodeling via actin; integrin mediated cell adhesion and movement of cell/subcellular compartments. The purpose of this research was to evaluate the expression levels of ARPC1B in different prostate cancer cell lines and investigate its potential role in disease progression. ARPC1B expression was analysed using western blot and qRT-PCR in multiple cell lines. We found ARPC1B protein and mRNA levels to be upregulated in the PC3 cell line compared to other cell lines. To validate the role of ARPC1B, siRNA was used to knockdown ARPC1B in PC3 cells which resulted in significant reduction of cell proliferation as measured using the MTS assay. Reduced cell growth and/or reduced migration in cells with ARPC1b knocked down was also seen using scratch assays. Tissue expression levels were also investigated on a progression tissue microarray and showed increased intensity with disease progression from benign to localized cancer and castrate resistant disease. These data suggest that ARPC1B could be a valid prostate cancer marker.	en_US
dc.identifier.citation	Hend, Z. (2019). ARPC1B Gene: As a Potential Novel Prostate Cancer Driver (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.	en_US
dc.identifier.doi	http://dx.doi.org/10.11575/PRISM/37368
dc.identifier.uri	http://hdl.handle.net/1880/111382
dc.language.iso	eng	en_US
dc.publisher.faculty	Cumming School of Medicine	en_US
dc.publisher.institution	University of Calgary	en
dc.rights	University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.	en_US
dc.subject	prostate cancer. Proliferation. Prostate cancer biomarker. metastasis	en_US
dc.subject.classification	Oncology	en_US
dc.title	ARPC1B Gene: As a Potential Novel Prostate Cancer Driver	en_US
dc.type	master thesis	en_US
thesis.degree.discipline	Medicine – Biochemistry and Molecular Biology	en_US
thesis.degree.grantor	University of Calgary	en_US
thesis.degree.name	Master of Science (MSc)	en_US
ucalgary.item.requestcopy	true	en_US